10-Q: Anebulo Pharmaceuticals to Go Private, Delist from Nasdaq

Anebulo Pharmaceuticals reports reduced net loss and a strategic shift to pediatric cannabis toxicity treatment, while initiating a going-private transaction.

Summary

• Net loss for the six months ended December 31, 2025, improved to $4.16 million from $4.66 million in the prior year period.
• Cash and cash equivalents decreased to $9.04 million as of December 31, 2025, from $11.63 million at June 30, 2025.
• The company is prioritizing the development of an intravenous (IV) formulation of selonabant for pediatric unintentional cannabis poisoning, believing it offers a faster path to approval compared to the oral adult acute cannabinoid intoxication (ACI) treatment.
• Anebulo completed a tender offer to purchase 300,000 shares of common stock at $3.50 per share, totaling approximately $1.05 million, as part of its plan to go private.
• The company announced its intent to voluntarily delist its common stock from the Nasdaq Capital Market and subsequently deregister with the SEC to suspend reporting obligations.
• Received a second-year grant award of approximately $1.0 million from the National Institute on Drug Abuse (NIDA) for the development of IV selonabant, bringing the total grant to approximately $1.9 million.
• Research and development expenses decreased by $0.56 million for the six months ended December 31, 2025, primarily due to lower contract manufacturing costs in the current period.
• General and administrative expenses increased by $0.44 million for the six months ended December 31, 2025, driven by accrued executive bonuses and professional fees related to the going-private transaction, partially offset by lower stock-based compensation.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing with a moderately positive sentiment. While financial performance shows improvement in net loss and operating cash burn, the going-private transaction introduces significant liquidity and information risks for existing public shareholders. The strategic focus on pediatric IV selonabant is a strong positive, addressing an unmet need with grant support, but the overall financial stability remains dependent on future funding.

Positives

• Net loss decreased by $0.51 million for the six months ended December 31, 2025, compared to the same period in 2024, indicating improved financial performance.
• Net cash used in operating activities decreased by $0.51 million, from $3.10 million in 2024 to $2.59 million in 2025, reflecting more efficient cash management.
• Grant income significantly increased to $0.56 million for the six months ended December 31, 2025, from $0.42 million in the prior year, providing non-dilutive funding for development.
• Interest income rose substantially to $0.19 million for the six months ended December 31, 2025, from $0.03 million in 2024, due to higher average cash balances.
• The strategic prioritization of IV selonabant for pediatric cannabis toxicity addresses a recognized unmet medical need and potentially offers a faster regulatory pathway.
• Successful completion of IND-enabling activities and scale-up of IV selonabant formulation, supported by NIDA grants, demonstrates progress in product development.
• The company's intellectual property portfolio is robust, with three issued U.S. patents and rights to additional patent applications, providing protection through 2040 for key aspects of selonabant.

Negatives

• The company continues to incur significant operating losses, with an accumulated deficit of $78.05 million as of December 31, 2025.
• Cash and cash equivalents decreased by $2.59 million from June 30, 2025, to December 31, 2025, indicating ongoing cash burn.
• The decision to go private will result in the delisting of common stock from Nasdaq and suspension of SEC reporting, leading to significantly less public information and increased illiquidity for remaining stockholders.
• Future capital raises, which are anticipated, may cause substantial dilution to existing stockholders, especially given the requirement to issue shares for any drawn funds under the Loan Agreement.
• General and administrative expenses increased by $0.44 million for the six months ended December 31, 2025, partly due to costs associated with the going-private transaction.

Risks

• The company has not generated any revenue since inception and expects to incur future losses, potentially never achieving profitability.
• Future success is uncertain and subject to expenses, difficulties, complications, and delays common in clinical development, including unanticipated clinical trial delays, poor data, and changes in the regulatory landscape.
• The company will need to raise additional capital beyond the available Loan Agreement funds, which may be unavailable on acceptable terms or at all, potentially forcing delays, scaling back, or elimination of product development.
• Issuing equity or equity-linked securities for future capital raises will dilute existing stockholders, and debt financing may involve restrictive covenants or liens on assets.
• The going-private transaction carries risks, including the possibility that the number of record holders could exceed 300 during the deregistration process, preventing the filing of Form 15 and forcing the company to continue as a public company trading on the OTC market after delisting from Nasdaq.
• A U.S. federal government shutdown could adversely affect business operations by delaying regulatory approvals, hindering strategic transactions, increasing legal and compliance risks, and disrupting grant funding.
• Inadequate funding or disruptions at the FDA, SEC, NIH, or USPTO could delay regulatory submissions, clinical trials, and grant disbursements, negatively impacting development timelines and financial condition.
• Uncertainty exists regarding how the new administration will modify FDA and other regulatory agency requirements and policies, potentially creating a more challenging or costly environment for therapeutic development.

Future Outlook

The company expects to continue incurring significant operating losses and negative cash flows as it advances clinical development. Cash and cash equivalents, along with available funding under the Loan Agreement, are projected to fund operations for at least the next 12 months. The company intends to complete its going-private transaction, delisting from Nasdaq around February 27, 2026, and filing for deregistration with the SEC around the same date, aiming to suspend its reporting obligations. Research and development expenses are expected to increase with ongoing clinical studies, while general and administrative expenses are anticipated to decrease once the company ceases to be public.

Management Comments

• Management believes the data from the Netherlands Trial provides support for the development pathway of selonabant.
• The FDA acknowledged the unmet need for a treatment for children exposed to cannabis toxicity and proposed a close, ongoing collaboration to efficiently advance the selonabant program for the pediatric indication.
• The decision to prioritize the development of an intravenous treatment for children is driven by multiple factors, including the recent development of a suitable IV selonabant formulation and increasing recognition among clinicians of this growing, unmet medical need.
• Management believes the path to approval for an oral treatment for adult ACI may be facilitated by an initial approval for intravenous treatment of unintentional cannabis poisoning in the pediatric population.
• Management believes the recent decision by the United States Department of Justice to support the rescheduling of marijuana will ultimately lead to increased use of cannabis-containing products, potentially including edibles that cause unintentional cannabis poisoning in children.
• Management believes Anebulo is uniquely positioned to become a provider of a rapid and clinically impactful solution for Emergency Departments to treat pediatric patients suffering from unintentional cannabis poisoning.

Industry Context

StockSavvy.ai notes that Anebulo Pharmaceuticals' strategic shift to focus on an intravenous formulation of selonabant for pediatric cannabis-induced toxicity aligns with a growing public health concern, particularly as cannabis legalization expands across the U.S. The increasing incidence of unintentional cannabis poisoning in children highlights a significant unmet medical need, which the FDA has acknowledged. The company's focus on this vulnerable population, coupled with the potential for a faster regulatory timeline, positions it to address a critical gap in emergency medical treatments. The broader industry trend of cannabis rescheduling by the U.S. Department of Justice is expected to further increase cannabis use, potentially exacerbating the problem of accidental exposures and reinforcing the market need for effective antidotes.

Comparison to Industry Standards

• The company's accumulated deficit of $78.05 million is typical for clinical-stage pharmaceutical companies that have not yet commercialized a product, as significant capital is required for research and development without corresponding revenue.
• The NIDA grant funding of approximately $1.9 million for IV selonabant development is a positive indicator, as government grants are a common and non-dilutive funding source for early-stage drug development, particularly for unmet medical needs like pediatric cannabis toxicity.
• The company's intellectual property protection, with patents extending through 2040, is a standard and crucial asset for pharmaceutical companies, providing a competitive moat for its lead product candidate, selonabant.

Corporate Governance

Related Party Transactions

• The company has a sublease for its principal executive office in Lakeway, Texas, with a related party for approximately $400 per month.
• The Loan Agreement (formerly LSA) was entered into with 22NW, LP and JFL Capital Management LLC. Joseph F. Lawler, M.D., Ph.D., the company's founder and a board member, is the founder and Managing Member of JFL. Aron R. English, President and Portfolio Manager of 22NW, and Nathaniel Calloway, lead for 22NW, LPs biotechnology investments, are also board members.

Stakeholder Impact

• Shareholders who did not participate in the tender offer will face significantly reduced liquidity and less public information due to the delisting from Nasdaq and deregistration with the SEC.
• Smallest stockholders benefited from the tender offer, providing an opportunity to sell shares at a premium in a limited trading market.
• Employees and management may benefit from the reduced administrative burden and costs associated with being a private company, potentially allowing more focus on core drug development.
• The strategic focus on pediatric cannabis toxicity treatment could benefit patients and healthcare providers by addressing a critical unmet medical need.
• Creditors and potential future investors will have less public financial and operational information available, which could affect future financing terms.

Next Steps

• Continue the ongoing single ascending dose (SAD) study of IV selonabant in healthy adults.
• Continue the observational study in emergency department patients, with a modified focus on pediatric patients.
• File a Form 25 with the SEC to delist common stock from Nasdaq on or about February 17, 2026.
• File a Form 15 with the SEC to terminate registration under the Securities Exchange Act of 1934 on or about February 27, 2026.
• Seek additional funding through equity and debt financings or collaboration, license, and development agreements.

Key Dates

Recommendation

The decision to go private and delist from Nasdaq will severely impact the liquidity and transparency of Anebulo's common stock. While the company's strategic shift to pediatric IV selonabant is promising, the lack of public reporting and the potential for trading only on the illiquid OTC market (if at all) makes the stock highly unattractive for most investors. The tender offer provided an exit opportunity at a premium, and remaining shareholders face significant uncertainty regarding future valuation and ability to trade shares. Seasoned investors would likely view this as a strong signal to exit their position, especially given the inherent risks of a clinical-stage biotech combined with the loss of public market access.

Keywords

Anebulo Pharmaceuticals, Selonabant, Cannabis Toxicity, Acute Cannabinoid Intoxication, Pediatric Cannabis Poisoning, Clinical Stage Pharmaceutical, SEC Filing, 10-Q, Going Private, Delisting, Nasdaq, NIDA Grant, Drug Development, Biotechnology, Pharmaceuticals